Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease.
Inflamm Bowel Dis
; 28(11): 1781-1786, 2022 11 02.
Article
in English
| MEDLINE | ID: covidwho-1784354
Herein, we evaluated the humoral immunogenicity of a third coronavirus disease 2019 messenger RNA vaccine dose in patients with inflammatory bowel diseases. All patients displayed a humoral immune response, and median antibody concentrations were higher after the third dose than after completion of the 2-dose series.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Inflammatory Bowel Diseases
/
Colitis, Ulcerative
/
COVID-19
Type of study:
Experimental Studies
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Inflamm Bowel Dis
Journal subject:
Gastroenterology
Year:
2022
Document Type:
Article
Affiliation country:
Ibd
Similar
MEDLINE
...
LILACS
LIS